Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance by Raymond Oppong, Richard D Smith, Paul Little, Theo Verheij, Christopher C Butler, Herman Goossens, Samuel Coenen, Michael Moore, and Joanna Coast BJGP Volume 66(650):e633-e639 August 25, 2016 ©2016 by British Journal of General Practice
Incremental net benefits with and without the cost of resistance. Incremental net benefits with and without the cost of resistance. INB = incremental net benefit. Raymond Oppong et al. Br J Gen Pract 2016;66:e633-e639 ©2016 by British Journal of General Practice
Cost-effectiveness acceptability curve (amoxicillin versus placebo) with and without resistance. Raymond Oppong et al. Br J Gen Pract 2016;66:e633-e639 ©2016 by British Journal of General Practice